Endo International PLC (ENDP) Expected to Announce Quarterly Sales of $780.75 Million
Equities analysts forecast that Endo International PLC (NASDAQ:ENDP) (TSE:ENL) will announce sales of $780.75 million for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Endo International PLC’s earnings. The lowest sales estimate is $763.87 million and the highest is $802.00 million. Endo International PLC posted sales of $884.34 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 11.7%. The business is expected to announce its next earnings report on Tuesday, November 14th.
According to Zacks, analysts expect that Endo International PLC will report full year sales of $780.75 million for the current fiscal year, with estimates ranging from $3.43 billion to $3.51 billion. For the next year, analysts forecast that the business will post sales of $3.15 billion per share, with estimates ranging from $2.91 billion to $3.41 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Endo International PLC.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last posted its earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The company had revenue of $875.73 million during the quarter, compared to the consensus estimate of $832.66 million. During the same period in the previous year, the firm posted $0.86 earnings per share. The company’s revenue for the quarter was down 4.9% compared to the same quarter last year.
A number of analysts have recently commented on ENDP shares. ValuEngine upgraded Endo International PLC from a “hold” rating to a “buy” rating in a report on Monday. Goldman Sachs Group, Inc. (The) initiated coverage on Endo International PLC in a report on Thursday, September 28th. They set a “sell” rating and a $7.00 price objective for the company. Zacks Investment Research upgraded Endo International PLC from a “strong sell” rating to a “hold” rating in a report on Monday, September 25th. Piper Jaffray Companies reissued a “hold” rating and issued a $9.00 target price on shares of Endo International PLC in a research report on Sunday, September 17th. Finally, Mizuho reissued a “buy” rating and issued a $14.00 target price (down previously from $19.00) on shares of Endo International PLC in a research report on Tuesday, September 12th. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have issued a buy rating to the company. Endo International PLC currently has an average rating of “Hold” and an average target price of $12.80.
WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/04/endo-international-plc-endp-expected-to-announce-quarterly-sales-of-780-75-million.html.
In related news, CFO Blaise Coleman acquired 6,500 shares of the firm’s stock in a transaction on Tuesday, August 15th. The shares were purchased at an average cost of $7.89 per share, for a total transaction of $51,285.00. Following the completion of the acquisition, the chief financial officer now directly owns 13,729 shares in the company, valued at $108,321.81. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, COO Terrance J. Coughlin acquired 20,000 shares of the firm’s stock in a transaction on Thursday, August 10th. The stock was bought at an average price of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the acquisition, the chief operating officer now owns 181,369 shares of the company’s stock, valued at $1,396,541.30. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 36,000 shares of company stock worth $279,460. 0.50% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of ENDP. OppenheimerFunds Inc. raised its position in shares of Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after purchasing an additional 1,857,678 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Endo International PLC by 38.7% during the 1st quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock worth $25,345,000 after buying an additional 633,904 shares during the period. Diamond Hill Capital Management Inc. bought a new stake in shares of Endo International PLC during the 2nd quarter worth about $5,454,000. Ameriprise Financial Inc. boosted its holdings in shares of Endo International PLC by 685.0% during the 1st quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock worth $6,185,000 after buying an additional 483,545 shares during the period. Finally, American International Group Inc. boosted its holdings in shares of Endo International PLC by 451.5% during the 1st quarter. American International Group Inc. now owns 396,887 shares of the company’s stock worth $4,429,000 after buying an additional 324,922 shares during the period. 90.71% of the stock is currently owned by institutional investors.
Endo International PLC (NASDAQ ENDP) opened at 8.71 on Wednesday. Endo International PLC has a 12-month low of $7.41 and a 12-month high of $21.87. The stock’s 50 day moving average is $8.67 and its 200-day moving average is $10.65. The company’s market cap is $1.94 billion.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.